282 References Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med (2009) 361(21):2066-78. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol (2006) 3(7):390-407. Schroeder KW, TremaineWJ, IlstrupDM. Coated oral 5-aminosalicylic acid therapy for mildly tomoderately active ulcerative colitis. A randomized study. N Engl J Med (1987) 317(26):1625-9. Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc (2004) 60(4):505-12. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol (2004) 99(1):91-6. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut (2010) 59(9):1200-6. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut (2007) 56(4):453-5. Rutgeerts P, Feagan BG, Lichtenstein GR Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology (2004) 126(2):402-13. Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, crosssectional imaging and biomarkers in Crohn’s disease monitoring. Gut (2013) 62(12):1806-16. Minderhoud IM, Samsom M, Oldenburg B. What predicts mucosal inflammation in Crohn’s disease patients? Inflamm Bowel Dis (2007) 13(12):1567-72. Cellier C, Sahmoud T, Froquel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Études Thérapeutiques des Affections Inflammatoires Digestives. Gut (1994) 35(2):231-5. Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastoenterol Hepatol (2008) 6(11):1218-24. Carlsen K, Riis LB, Elsberg H, Maagaard L, Thorkilgaard T, Sørbye SW, et al. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand J Gastroenterol (2018) 53(7):825-30. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology (2011) 140(6):1817-26. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol (2008) 103(1):162-9. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 55(3):426-31. Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev (2017) 16(4):416-24. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol (2014) 14(5):329-42. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol (2002) 20:495-549. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Chapter 8
RkJQdWJsaXNoZXIy MjY0ODMw